--Reflects Fund's Commitment to Meet the Financing Needs of European and Asian Healthcare Companies and Institutions-- NEW YORK, July 24
NEW YORK, July 24 /PRNewswire/ -- Paul Capital Partners today announced
that Ken Macleod, Ph.D., has been promoted to Partner. Based in Paul
Capital's London office, Dr. Macleod is responsible for sourcing, evaluating
and negotiating European and Asian healthcare investment opportunities for the
Paul Capital Healthcare funds.
"Since he joined Paul Capital four years ago, Ken has strengthened our
presence in the European and Asian healthcare markets and helped us form many
mutually beneficial partnerships," said Walter Flamenbaum, M.D., a Partner of
Paul Capital Partners. "He embodies our commitment to helping healthcare
companies, institutions and inventors advance their goals by identifying
strategic solutions to their financial and asset management needs. Ken's
promotion to Partner reflects his demonstrated ability to identify promising
healthcare investment opportunities and underscores Paul Capital's dedication
to expanding its position in the global healthcare arena."
Most recently, in April 2008, Paul Capital Healthcare invested up to $28
million in Plethora Solutions Holdings PLC and euro 18.4 million in Vernalis
plc, both of which are based in the U.K. To date, the Paul Capital Healthcare
funds have invested $395 million in 14 transactions in Europe and Asia.
"A growing number of European and Asian healthcare companies and
institutions recognize that in order to realize their innovative potential
they require an equally innovative approach to creating value and accessing
capital," said Dr. Macleod. "With more than $940 million committed to 37
healthcare investments, and similar leadership in the areas of private equity
secondaries and venture capital funds of funds, Paul Capital provides funds
that help leading-edge companies, institutions and individuals meet diverse
strategic objectives. I am very pleased to become a partner of this highly
regarded team."
Dr. Macleod provides a strong operational background in the pharmaceutical
and biotechnology industries, where he previously held senior management
positions over a 15-year career at Serono, Abbott Laboratories and Beecham
Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a
Venture Partner at Schroder Ventures Life Sciences where he was responsible
for deal sourcing, evaluation and negotiation of pharmaceutical investment
opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK
and his B.Sc. with honors in Biology from the University of Manchester, UK.
About Paul Capital Partners and Paul Capital Healthcare
Founded in 1991, Paul Capital manages $6.6 billion in capital commitments
for its three investment platforms that include private equity secondaries,
healthcare royalty and revenue interests, and venture capital fund of funds.
The firm has offices in Hong Kong, London, New York, Paris, San Francisco, Sao
Paulo and Toronto.
Through its funds, Paul Capital Healthcare is one of the largest dedicated
healthcare investors globally, with more than $1.4 billion in equity capital
commitments and debt facilities under management. Combined, the Paul Capital
Healthcare funds have invested more than $940 million in the pharmaceutical,
biotechnology, and medical device sectors. These investments are focused on
commercial stage companies and products, and consist of investments in the
form of royalties, revenue interests, debt and equity. Additional information
on Paul Capital Healthcare can be found at www.paulcapitalhealthcare.com.
Contact:
Paul Capital Partners
Ken Macleod, Partner
Tel: +44(0)20-7514-0754
Email: kmacleod@paulcap.com
Joshua Glaser, Director of Investor Relations
Tel: +1-646-264-1169
Email: jglaser@paulcap.com
Lazar Partners
Stephanie Seiler
Tel: +1-646-871-8487
Tel: +1-206-713-0124
Email: sseiler@lazarpartners.com
SOURCE Paul Capital Partners
